Abstracts tagged "Hydroxychloroquine"

Abstract Number: 737 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Whole Blood Levels Do Not Associate with Hydroxychloroquine Retinopathy
Michelle Petri¹, Wei Fu² and Syed Mahmood Shah³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The American Academy of Ophthalmology guidelines on hydroxychloroquine retinopathy were recently revised (Ophthalmology 2016;1-9). These guidelines recommend optical coherence tomography (OCT) with multifocal electroretinogram…
Abstract Number: 741 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients
Samya Mohammad, Megan E. B. Clowse, Amanda Eudy and Lisa Criscione-Schreiber, Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: Hydroxychloroquine (HCQ) is frequently used to treat autoimmune diseases. The HCQ package insert and online drug information resources report an increased risk of hemolytic…
Abstract Number: 751 • 2016 ACR/ARHP Annual Meeting
Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Michelle Petri¹, Ying Qu², John Conklin³, Kelley Brady⁴, Robert Apilado⁵ and Thierry Dervieux⁶, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴R&D, Exagen Diagnostics, Vista, CA, United Kingdom, ⁵Exagen Diagnostics, vista, CA, United Kingdom, ⁶Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: We evaluated the relationships between disease activity measures and C4d split products on erythrocytes (EC4d) in SLE subjects from a subset of the Hopkins…
Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Rajaie Namas¹, Corey Powell² and J. Michelle Kahlenberg³, ¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ²Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…
Abstract Number: 1490 • 2016 ACR/ARHP Annual Meeting
Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Claire Rempenault¹, Thomas Barnetche², Jacques Morel³, Cédric Lukas⁴, Cécile Gaujoux-Viala⁵, Bernard Combe⁶ and Charlotte Hua⁷, ¹Rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients. Hydroxychloroquine (HCQ) has been shown to improve major outcomes like…
Abstract Number: 1504 • 2016 ACR/ARHP Annual Meeting
Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Karen Ferez-Blando¹, Hilda Fragoso-Loyo², Alfredo Ponce de León³, Sergio Ponce de Leon-Rosales⁴ and Yemil Atisha-Fregoso¹, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Direccion de Enseñanza, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires chronic immunosuppressive treatment. Urinary tract infections (UTI) are common among patients with RA. It…
Abstract Number: 1817 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long…
Abstract Number: 2047 • 2016 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Adey Berhanu³, Cesar Fors-Nieves⁴, Ummara Shah⁵, Patrick Brown⁶, Carl Laskin⁷, Nathalie Morel⁸, Kateri Levesque⁹, Jill P. Buyon¹⁰, Earl Silverman⁶ and Peter M. Izmirly¹¹, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Rheumatology Fellowship Program, NYU Langone Medical Center/NYU School of Medicine, New York, NY, ⁴Division of Rheumatology, NYU School of Medicine, New York, NY, ⁵Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁶University of Toronto, Toronto, ON, Canada, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁹Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ¹⁰Medicine, Tisch Hospital, New York, NY, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Histopathologic studies of cutaneous neonatal lupus erythematosus (cNLE) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in…
Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Cesar Fors-Nieves³, Ummara Shah⁴, Patrick Brown⁵, Carl Laskin⁶, Nathalie Morel², Kateri Levesque⁷, Jill P. Buyon⁸, Earl Silverman⁹ and Peter M. Izmirly¹⁰, ¹Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, ²Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ³Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁵University of Toronto, Toronto, ON, Canada, ⁶Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ⁸NYU School of Medicine, New York, NY, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
Myriam Guevara¹, Bernard NG¹ and Nancy Gove², ¹Rheumatology, University of Washington, Seattle, WA, ²Biostatistics, Seattle Children's, Seattle, WA
Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…
Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 2483 • 2015 ACR/ARHP Annual Meeting
Adherence to 2011 American Academy of Ophthalmology Guidelines to Perform Objective Screening Tests for Detection of Antimalarial Retinal Toxicity Is Suboptimal
Sarah Haserodt¹, Chris Tonner², Sara G. Murray³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/ Rheumatology, UCSF/ San Francisco VA, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA
Background/Purpose: American Academy of Ophthalmology (AAO) 2011 guidelines recommend that patients receiving hydroxychloroquine (HCQ) or chloroquine (CQ) undergo regular screening for retinal toxicity with 1…
Abstract Number: 2374 • 2014 ACR/ARHP Annual Meeting
Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients
Jose Felix Restrepo¹, Inmaculada del Rincon², Emily Molina³, Daniel Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine/Clinical Immunology, UTHSCSA, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center, San Antonio, TX, ⁴Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁵Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality in rheumatoid arthritis (RA). CVD risk factor reduction, such as reducing…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid
Ou Jin¹, Xi Zhang¹, Lingkai Fang¹, Qiuxia Li¹, Hongyue Huang¹, Zhiming Lin², Zetao Liao¹, Dongfang Lin¹, Chengcheng Hou¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].